An Inhibitor of Oxidative Phosphorylation Exploits Cancer Vulnerability
Metabolic reprograming is an emerging hallmark of tumor biology and an actively pursued opportunity in discovery of oncology drugs. Extensive efforts have focused on therapeutic targeting of glycolysis, whereas drugging mitochondrial oxidative phosphorylation (OXPHOS) has remained largely unexplored, partly owing to an incomplete understanding of tumor contexts in which OXPHOS is essential. Here, we report […]
An Inhibitor of Oxidative Phosphorylation Exploits Cancer Vulnerability Read More »